Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries.

Future Oncology
Zdravko VassilevJihong Zong

Abstract

Aim: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Patients & methods: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. Results: SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4-88.4), 101.7 (95% CI: 90.3-114.5) and 59 (95% CI: 50-68) per 1000 person-years in German, Swedish and US cohorts, respectively. Conclusion: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.

References

Apr 29, 1998·American Journal of Epidemiology·L E Daly
Aug 24, 1999·Cancer Metastasis Reviews·P H Lange, R L Vessella
Apr 16, 2004·The New England Journal of Medicine·G David Roodman
Sep 17, 2004·Endocrine-related Cancer·Howard I ScherWayne D Tilley
Jan 1, 2010·Mayo Clinic Proceedings·Manish Kohli, Donald J Tindall
Feb 9, 2010·Trends in Endocrinology and Metabolism : TEM·Karen E Knudsen, Trevor M Penning
Dec 21, 2010·Expert Review of Anticancer Therapy·Carlo BuonerbaGiuseppe Di Lorenzo
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
May 9, 2012·International Journal of Epidemiology·Mieke Van HemelrijckUNKNOWN NPCR and PCBaSe Sweden
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Oct 10, 2012·Anti-cancer Drugs·Giuseppe Di LorenzoSabino De Placido
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators
Jul 19, 2014·Acta Oncologica·Katarina TomicPär Stattin
May 8, 2015·Leukemia & Lymphoma·Nuchanan Areethamsirikul, Donna E Reece
May 20, 2015·Cancer Treatment Reviews·Maria KatsogiannouPalma Rocchi
Jul 18, 2015·Cancer Letters·Arndt Katzenwadel, Philipp Wolf
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola
Aug 17, 2016·Pharmacoepidemiology and Drug Safety·Katsiaryna BykovJoshua J Gagne
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators
Apr 26, 2018·The New England Journal of Medicine·Oliver Sartor, Johann S de Bono
Apr 27, 2018·The New England Journal of Medicine·Juan F Rodriguez‑Moreno, Jesus Garcia‑Donas
Oct 18, 2018·Cancer Medicine·Matias RiihimäkiKari Hemminki
Jun 1, 2019·The New England Journal of Medicine·Kim N ChiUNKNOWN TITAN Investigators
Jun 4, 2019·The New England Journal of Medicine·Ian D DavisUNKNOWN ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.